Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

Purpose: Binge eating disorder (BED) is a psychological disorder that poses several functional consequences for those affected. Management of BED centers around psychological and pharmacological treatment modalities, which have been associated with variable efficacy and the potential for severe adverse effects. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), approved by the Food and Drug Administration for conditions such as diabetes and weight management, are an emerging therapy of interest in BED.

Summary: In this case report, we describe use of dulaglutide for treatment of a patient with BED, obesity, and type 2 diabetes mellitus. The patient's baseline binge eating scale (BES) score, glycated hemoglobin level, body mass index (BMI), and weight were obtained. Following these baseline assessments, dulaglutide 0.75 mg once weekly was initiated to optimize management of the patient's type 2 diabetes. Follow-up measurements were obtained 6 weeks after initiation, at which time reductions in the patient's BES score, BMI, weight, and BED symptoms were observed. Moreover, dulaglutide was well tolerated without adverse drug events.

Conclusion: This case report describes the use of dulaglutide in the management of mild BED in the setting of comorbid type 2 diabetes and obesity. Further research is necessary to evaluate the long-term effectiveness of GLP-1 RAs in the management of BED and to determine the optimal duration and dose.

© American Society of Health-System Pharmacists 2025. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

免责声明： 为了尽快发布文章，AJHP 尽可能在论文被接受后立即在线发表手稿。已接受的手稿经过同行评审和校对，但在技术排版和作者审核之前就先在线发表了。这些手稿不是最终版本，并将在以后的时间用按照 AJHP 格式编排且由作者审核过的最终文章进行替换。

目的： 暴食症（BED）是一种心理障碍，会给患者带来多种功能后果。BED 的管理主要集中在心理和药物治疗上，这两种方法的效果各不相同，并有潜在的严重不良反应风险。由美国食品药品监督管理局批准用于糖尿病和体重管理等疾病的胰高血糖素样肽-1 受体激动剂（GLP-1 RAs），正在成为 BED 治疗的一种新兴疗法。

摘要： 在这份案例报告中，我们描述了使用度拉唐肽治疗患有暴食症、肥胖和 2 型糖尿病患者的病例。在基线时获取患者暴食量表（BES）评分、糖化血红蛋白水平、体重指数（BMI）及体重数据。完成这些基线评估后，在优化管理患者的 2 型糖尿病方面启动每周一次的度拉唐肽 0.75 毫克治疗。在治疗 6 周后获得随访测量，此时观察到患者 BES 评分、BMI、体重和暴食症症状均有减少。此外，度拉唐肽耐受性良好且未发生不良药物事件。

结论： 本案例报告描述了使用度拉唐肽在患有共病 2 型糖尿病及肥胖的轻度 BED 管理中的应用。为进一步评估 GLP-1 RAs 在管理 BED 的长期有效性以及确定最佳疗程和剂量，仍需进一步研究。

© American Society of Health-System Pharmacists 2025. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.